Almirall (ALM) Hisse Özeti
Almirall, S.A. İspanya, Avrupa, Orta Doğu, Amerika Birleşik Devletleri, Asya ve Afrika'da cilt sağlığı odaklı bir biyofarmasötik şirketi olarak faaliyet göstermektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 4/6 |
| Geçmiş Performans | 5/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 3/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden ALM için herhangi bir risk tespit edilmedi.
ALM Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Almirall, S.A. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | €10.50 |
| 52 Haftanın En Yüksek Seviyesi | €13.98 |
| 52 Haftanın En Düşük Seviyesi | €10.36 |
| Beta | 0.17 |
| 1 Aylık Değişim | -1.69% |
| 3 Aylık Değişim | -7.73% |
| 1 Yıllık Değişim | -5.75% |
| 3 Yıllık Değişim | 12.24% |
| 5 Yıllık Değişim | -25.69% |
| Halka arzdan bu yana değişim | -30.00% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 28
ALM: Dermatology Pipeline Progress Will Drive Future Upside Repricing
Analysts have adjusted the Almirall price target to about €17.50 from about €16.57, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts covering Almirall are using a range of sector signals to frame their updated views, even when those signals come from different parts of the market.
Anlatı Güncellemesi • Jul 12
ALM: Future Re-Rating Will Rely On Dermatology Pipeline And R&D Partnerships
Analysts have lifted their fair value estimate for Almirall to €14.58 from €13.91, reflecting updated assumptions for revenue growth, profit margins and a slightly lower discount rate. Together, these factors support a modestly higher long term price target and a marginally lower future P/E multiple.Recent updates
Anlatı Güncellemesi • Jul 28
ALM: Dermatology Pipeline Progress Will Drive Future Upside Repricing
Analysts have adjusted the Almirall price target to about €17.50 from about €16.57, reflecting updated assumptions around fair value, discount rate, revenue growth, profit margins and future P/E expectations. Analyst Commentary Analysts covering Almirall are using a range of sector signals to frame their updated views, even when those signals come from different parts of the market.Anlatı Güncellemesi • Jul 12
ALM: Future Re-Rating Will Rely On Dermatology Pipeline And R&D Partnerships
Analysts have lifted their fair value estimate for Almirall to €14.58 from €13.91, reflecting updated assumptions for revenue growth, profit margins and a slightly lower discount rate. Together, these factors support a modestly higher long term price target and a marginally lower future P/E multiple.Anlatı Güncellemesi • Feb 03
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have nudged their price target on Almirall higher to €13.91 from €13.69, reflecting updated assumptions on revenue growth, profit margins and future P/E, despite a recent downgrade in stance from BNP Paribas. Analyst Commentary Analysts are sending mixed signals on Almirall, with a higher price target sitting alongside a more cautious rating.Anlatı Güncellemesi • Jan 19
ALM: Future Re-Rating Will Rely On Dermatology Pipeline And Execution
Analysts slightly trimmed their price target for Almirall to €13.69 from €13.86, citing updated assumptions around revenue growth, profit margins, and future P/E expectations. What's in the News Almirall plans to start a phase III study in the first half of 2026 evaluating Lebrikizumab (Ebglyss) for nummular eczema.Anlatı Güncellemesi • Jan 05
ALM: Future Re-Rating Will Depend On Pipeline Execution And Ebglyss Ramp-Up
Narrative update on Almirall Analysts have raised their price target on Almirall to €14.50, citing what they see as a still-compelling valuation, along with expectations for Ebglyss ramp-up, upcoming clinical readouts, and potential in-licensing and M&A to support the mid-stage pipeline. Analyst Commentary Recent research points to a target price of €14.50 for Almirall, with the view that the shares still offer a compelling entry point despite a prior rebound in the stock.Anlatı Güncellemesi • Dec 17
ALM: Future Re-Rating Will Hinge On Ebglyss Uptake And Pipeline Delivery
Analysts have modestly raised their price target on Almirall to EUR 14.50, citing expectations for a continued valuation re-rating supported by the ramp up of Ebglyss, upcoming clinical readouts, and potential in-licensing and M&A to bolster the mid-stage pipeline. Analyst Commentary Analyst views on Almirall remain broadly positive, with recent coverage highlighting both upside drivers and execution risks as the company advances its dermatology portfolio.Analiz Makalesi • Dec 08
Market Cool On Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 2.6x is worth a...Anlatı Güncellemesi • Dec 03
ALM: Future Re-Rating Will Depend On Dermatology Execution And Pipeline Delivery
Analysts have modestly raised their 12 month price target for Almirall to EUR 14.50, citing expectations that a continued re rating driven by Ebglyss ramp up, upcoming clinical readouts, and potential in licensing and M&A could support upside from current levels. Analyst Commentary Analysts note that Almirall's investment case is increasingly driven by visible growth levers in medical dermatology, but also caution that execution on product ramps and pipeline milestones will be critical to sustaining the recent share price rebound.Anlatı Güncellemesi • Nov 19
ALM: Pipeline Milestones And Product Launch Momentum Will Drive Re-Rating
Analysts have increased their price target for Almirall from €13.30 to €13.87. They cite a compelling valuation, strong pipeline prospects, and expectations for continued growth driven by product launches and strategic developments.Analiz Makalesi • Nov 17
Almirall's (BME:ALM) Strong Earnings Are Of Good Quality
When companies post strong earnings, the stock generally performs well, just like Almirall, S.A.'s ( BME:ALM ) stock...Analiz Makalesi • Nov 13
Almirall, S.A. (BME:ALM) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a good week for Almirall, S.A. ( BME:ALM ) shareholders, because the company has just released its latest...Analiz Makalesi • Aug 19
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Jul 29
The Almirall, S.A. (BME:ALM) Interim Results Are Out And Analysts Have Published New Forecasts
Almirall, S.A. ( BME:ALM ) came out with its interim results last week, and we wanted to see how the business is...Yeni Anlatı • Jul 22
European Demographics Will Drive Advancements In Dermatology Treatments
Strong specialty product launches and robust R&D pipeline are expected to drive growth, improve margins, and boost Almirall's market position in innovative dermatology.Analiz Makalesi • May 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 44% Above Its Share Price
Key Insights The projected fair value for Almirall is €14.08 based on 2 Stage Free Cash Flow to Equity Current share...Analiz Makalesi • Mar 27
Why We're Not Concerned About Almirall, S.A.'s (BME:ALM) Share Price
With a median price-to-sales (or "P/S") ratio of close to 2.2x in the Pharmaceuticals industry in Spain, you could be...Analiz Makalesi • Mar 03
Statutory Profit Doesn't Reflect How Good Almirall's (BME:ALM) Earnings Are
Almirall, S.A. ( BME:ALM ) recently posted some strong earnings, and the market responded positively. Our analysis...Analiz Makalesi • Feb 12
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Extensively
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Dec 10
Almirall, S.A.'s (BME:ALM) Popularity With Investors Is Clear
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Analiz Makalesi • Nov 14
Almirall, S.A. (BME:ALM) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
Almirall, S.A. ( BME:ALM ) shareholders are probably feeling a little disappointed, since its shares fell 2.9% to €8.52...Analiz Makalesi • Nov 06
Almirall (BME:ALM) Has A Somewhat Strained Balance Sheet
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • Sep 07
Investors Continue Waiting On Sidelines For Almirall, S.A. (BME:ALM)
You may think that with a price-to-sales (or "P/S") ratio of 2x Almirall, S.A. ( BME:ALM ) is a stock worth checking...Analiz Makalesi • Jul 12
Almirall, S.A.'s (BME:ALM) Intrinsic Value Is Potentially 90% Above Its Share Price
Key Insights Using the 2 Stage Free Cash Flow to Equity, Almirall fair value estimate is €18.31 Current share price of...Analiz Makalesi • Apr 24
Market Participants Recognise Almirall, S.A.'s (BME:ALM) Revenues
There wouldn't be many who think Almirall, S.A.'s ( BME:ALM ) price-to-sales (or "P/S") ratio of 1.9x is worth a...Analiz Makalesi • Mar 20
These 4 Measures Indicate That Almirall (BME:ALM) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Dec 15
Here's Why Almirall (BME:ALM) Can Manage Its Debt Responsibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analiz Makalesi • Oct 03
Is There An Opportunity With Almirall, S.A.'s (BME:ALM) 21% Undervaluation?
Key Insights Almirall's estimated fair value is €11.86 based on 2 Stage Free Cash Flow to Equity Almirall's €9.37 share...Analiz Makalesi • Aug 24
We Think Almirall (BME:ALM) Can Stay On Top Of Its Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Hissedar Getirileri
| ALM | ES Pharmaceuticals | ES Pazar | |
|---|---|---|---|
| 7D | -2.1% | -1.1% | -1.3% |
| 1Y | -5.7% | -0.5% | 27.1% |
Getiri vs. Endüstri: ALM geçen yıl % -0.5 oranında getiri sağlayan Spanish Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: ALM geçen yıl % 27.1 oranında getiri sağlayan Spanish Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| ALM volatility | |
|---|---|
| ALM Average Weekly Movement | 3.1% |
| Pharmaceuticals Industry Average Movement | 2.6% |
| Market Average Movement | 3.0% |
| 10% most volatile stocks in ES Market | 6.3% |
| 10% least volatile stocks in ES Market | 0.6% |
İstikrarlı Hisse Senedi Fiyatı: ALM son 3 ayda Spanish piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: ALM 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 1943 | 2,097 | Carlos Gallardo Piqué | www.almirall.com |
Almirall, S.A. İspanya, Avrupa, Orta Doğu, Amerika Birleşik Devletleri, Asya ve Afrika'da cilt sağlığı odaklı bir biyofarmasötik şirketi olarak faaliyet göstermektedir. Şirket ürünlerini Psoriasis, atopik dermatit, akne, aktinik keratoz, onikomikoz, androjenik alopesi, onkodermatoloji ve yetim endikasyonları içeren cilt hastalıklarının yanı sıra sindirim sistemi ve metabolizma; sistemik kullanım için antienfektifler; kardiyovasküler, kas-iskelet, sinir ve solunum sistemi; dermatolojikler; genitoüriner sistem ve seks hormonları; immünostimülanlar; metabolizma ve sistematik hormonal preparatlar için sunmaktadır. Tıbbi dermatoloji için mRNA tabanlı tedavileri araştırmak ve geliştirmek üzere Etherna ile çok hedefli bir ortaklığı vardır.
Almirall, S.A. Temel Bilgiler Özeti
| ALM temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | €2.29b |
| Kazançlar(TTM) | €59.13m |
| Gelir(TTM) | €1.16b |
38.7x
F/K Oranı2.0x
P/S OranıALM aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| ALM gelir tablosu (TTM) | |
|---|---|
| Gelir | €1.16b |
| Gelir Maliyeti | €265.62m |
| Brüt Kâr | €891.17m |
| Diğer Giderler | €832.04m |
| Kazançlar | €59.13m |
Son Raporlanan Kazançlar
Jun 30, 2026
Sonraki Kazanç Tarihi
Nov 09, 2026
| Hisse başına kazanç (EPS) | 0.27 |
| Brüt Marj | 77.04% |
| Net Kâr Marjı | 5.11% |
| Borç/Özkaynak Oranı | 21.2% |
ALM uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünTemettüler
1.8%
Mevcut Temettü Verimi68%
Ödeme OranıŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/08/18 12:51 |
| Gün Sonu Hisse Fiyatı | 2026/08/18 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Almirall, S.A. 28 Bu analistlerden 11, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Luis Arredondo | Banco de Sabadell. S.A. |
| null null | Banco de Sabadell. S.A. |
| Jaime Escribano | Banco Santander |